Stocks and Investing
Stocks and Investing
Thu, March 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Serge Belanger Maintained (XENE) at Strong Buy with Increased Target to $50 on, Mar 2nd, 2023
Serge Belanger of Needham, Maintained "Xenon Pharmaceuticals Inc." (XENE) at Strong Buy with Increased Target from $48 to $50 on, Mar 2nd, 2023.
Serge has made no other calls on XENE in the last 4 months.
There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Serge's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Serge
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $51 on, Tuesday, January 31st, 2023
- Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $60 on, Wednesday, December 14th, 2022
- Joseph Thome of "Cowen & Co." Initiated at Buy on, Monday, December 12th, 2022
- Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $50 on, Monday, November 28th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $49 on, Friday, November 11th, 2022
Contributing Sources